MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

10369	Companies
216098	Keywords
145810	Articles
114425	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/19/2025 at 14:30, 8 months 20 days ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
MIRA Pharmaceuticals, Inc. announces successful completion of Phase 1 Single Ascending Dose trial for oral Ketamir-2, preparing for U.S. Phase 2a trial in Q4 2025

Clinical Trial Phase 1 MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 08/12/2025 at 14:35, 8 months 27 days ago

MIRA Pharmaceuticals développe le kétamir-2 pour le traitement de la douleur neuropathique

Essais Cliniques Croissance Du Marché Médicaments Ketamir-2 Douleur Neuropathique
BRIEF

published on 08/12/2025 at 14:35, 8 months 27 days ago

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

Pharmaceuticals Clinical Trials Market Growth Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 08/12/2025 at 14:30, 8 months 27 days ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
MIRA Pharmaceuticals announces the acceptance of a manuscript in Frontiers in Pharmacology detailing Ketamir-2's efficacy in neuropathic pain, supporting Phase 2a trials by 2025

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pharmacology
BRIEF

published on 07/30/2025 at 13:35, 9 months 9 days ago

Le kétamir-2 topique de MIRA Pharmaceuticals est comparable à la morphine injectée dans une étude sur la douleur

Soulagement De La Douleur Étude Préclinique Kétamir-2 Topique Comparaison De La Morphine Traitement Localisé
BRIEF

published on 07/30/2025 at 13:35, 9 months 9 days ago

MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

Preclinical Study Pain Relief Topical Ketamir-2 Morphine Comparison Localized Treatment
PRESS RELEASE

published on 07/30/2025 at 13:30, 9 months 9 days ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
MIRA Pharmaceuticals announces new preclinical data showing topical Ketamir-2 provides effective pain relief comparable to injected morphine in animal models. The treatment has potential for both centralized and localized pain pathways

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Pain Relief
BRIEF

published on 07/29/2025 at 13:35, 9 months 10 days ago

MIRA Pharmaceuticals reçoit le feu vert de la FDA pour les essais du kétamir-2

Autorisation De La FDA Expansion Stratégique Ketamir-2 Douleur Neuropathique Essai De Phase 1
BRIEF

published on 07/29/2025 at 13:35, 9 months 10 days ago

MIRA Pharmaceuticals Receives FDA Green Light for Ketamir-2 Trials

FDA Clearance Phase 1 Trial Strategic Expansion Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 07/29/2025 at 13:30, 9 months 10 days ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
MIRA Pharmaceuticals advances non-opioid oral drug Ketamir-2 for neuropathic pain, clears FDA IND for Phase 2a, demonstrates potent effects in preclinical studies

FDA Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 05/08/2026 at 15:00, 19 minutes ago

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Published on 05/08/2026 at 14:55, 24 minutes ago

Nepra Foods Inc. to Present at the 16th Annual LD Micro Invitational
Published on 05/08/2026 at 14:30, 49 minutes ago

Unusual Machines Hosts Live Drone Ecosystem Demonstrations at XPONENTIAL 2026
Published on 05/08/2026 at 14:00, 1 hour 19 minutes ago

BlackBerry Announces Renewal of Normal Course Issuer Bid Share Buyback Program
Published on 05/08/2026 at 14:00, 1 hour 19 minutes ago

Loop Industries to Host Fourth Quarter 2025 Earnings Conference Call

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 15:08, 10 minutes ago

Siltronic AG's Annual General Meeting approves all agenda items by a clear majority
Published on 05/08/2026 at 14:16, 1 hour 2 minutes ago

Porsche sharpens focus on core business
Published on 05/08/2026 at 13:53, 1 hour 26 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/08/2026 at 13:35, 1 hour 43 minutes ago

DeFi Technologies Announces Partnership with OMFIF's Digital Monetary Institute and Confirms Participation at the Digital Money Summit 2026 in London
Published on 05/08/2026 at 13:05, 2 hours 13 minutes ago

Philadelphia Soccer 2026 Opens Media Credentialing and Fan Registration for FIFA Fan Festival™ Philadelphia

Les Echos

Published on 05/07/2026 at 19:15, 20 hours 4 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 20 hours 4 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 20 hours 13 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 20 hours 13 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 20 hours 19 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE